Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790966707> ?p ?o ?g. }
- W2790966707 endingPage "52" @default.
- W2790966707 startingPage "44" @default.
- W2790966707 abstract "PurposePlasma globotriaosylsphingosine (lyso-Gb3) is a promising secondary screening biomarker for Fabry disease. Here, we examined its applicability as a primary screening biomarker for classic and late-onset Fabry disease in males and females.MethodsBetween 1 July 2014 and 31 December 2015, we screened 2,360 patients (1,324 males) referred from 169 Japanese specialty clinics (cardiology, nephrology, neurology, and pediatrics), based on clinical symptoms suggestive of Fabry disease. We used the plasma lyso-Gb3 concentration, α-galactosidase A (α-Gal A) activity, and analysis of the α-Gal A gene (GLA) for primary and secondary screens, respectively.ResultsOf 8 males with elevated lyso-Gb3 levels (≥2.0 ng ml–1) and low α-Gal A activity (≤4.0 nmol h–1 ml–1), 7 presented a GLA mutation (2 classic and 5 late-onset). Of 15 females with elevated lyso-Gb3, 7 displayed low α-Gal A activity (5 with GLA mutations; 4 classic and 1 late-onset) and 8 exhibited normal α-Gal A activity (1 with a classic GLA mutation and 3 with genetic variants of uncertain significance).ConclusionPlasma lyso-Gb3 is a potential primary screening biomarker for classic and late-onset Fabry disease probands." @default.
- W2790966707 created "2018-03-29" @default.
- W2790966707 creator A5002329869 @default.
- W2790966707 creator A5002703388 @default.
- W2790966707 creator A5003696213 @default.
- W2790966707 creator A5003982307 @default.
- W2790966707 creator A5004853249 @default.
- W2790966707 creator A5008408499 @default.
- W2790966707 creator A5010287069 @default.
- W2790966707 creator A5010722476 @default.
- W2790966707 creator A5020425702 @default.
- W2790966707 creator A5021595831 @default.
- W2790966707 creator A5025325506 @default.
- W2790966707 creator A5027282442 @default.
- W2790966707 creator A5027629208 @default.
- W2790966707 creator A5032763504 @default.
- W2790966707 creator A5033327194 @default.
- W2790966707 creator A5047855327 @default.
- W2790966707 creator A5049498446 @default.
- W2790966707 creator A5051609037 @default.
- W2790966707 creator A5059381257 @default.
- W2790966707 creator A5063635467 @default.
- W2790966707 creator A5072798177 @default.
- W2790966707 creator A5077159139 @default.
- W2790966707 creator A5077533509 @default.
- W2790966707 creator A5079176935 @default.
- W2790966707 creator A5081317924 @default.
- W2790966707 creator A5082878951 @default.
- W2790966707 creator A5083957581 @default.
- W2790966707 creator A5084731978 @default.
- W2790966707 creator A5085203051 @default.
- W2790966707 creator A5088237353 @default.
- W2790966707 creator A5090493371 @default.
- W2790966707 date "2019-01-01" @default.
- W2790966707 modified "2023-10-06" @default.
- W2790966707 title "Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis" @default.
- W2790966707 cites W1480764651 @default.
- W2790966707 cites W1517384009 @default.
- W2790966707 cites W1583538379 @default.
- W2790966707 cites W1966318276 @default.
- W2790966707 cites W1970024336 @default.
- W2790966707 cites W1982263167 @default.
- W2790966707 cites W1993672365 @default.
- W2790966707 cites W2023258787 @default.
- W2790966707 cites W2026507072 @default.
- W2790966707 cites W2030162832 @default.
- W2790966707 cites W2039531402 @default.
- W2790966707 cites W2040332507 @default.
- W2790966707 cites W2053639086 @default.
- W2790966707 cites W2055821264 @default.
- W2790966707 cites W2061173128 @default.
- W2790966707 cites W2062214448 @default.
- W2790966707 cites W2068391573 @default.
- W2790966707 cites W2081735281 @default.
- W2790966707 cites W2084419856 @default.
- W2790966707 cites W2096596851 @default.
- W2790966707 cites W2097776291 @default.
- W2790966707 cites W2101425200 @default.
- W2790966707 cites W2103941204 @default.
- W2790966707 cites W2112453376 @default.
- W2790966707 cites W2123264974 @default.
- W2790966707 cites W2129958759 @default.
- W2790966707 cites W2131816649 @default.
- W2790966707 cites W2137603650 @default.
- W2790966707 cites W2143173170 @default.
- W2790966707 cites W2147019079 @default.
- W2790966707 cites W2165008949 @default.
- W2790966707 cites W2165232003 @default.
- W2790966707 cites W2296122401 @default.
- W2790966707 cites W2511544551 @default.
- W2790966707 cites W2518514057 @default.
- W2790966707 cites W2623428902 @default.
- W2790966707 cites W2805830 @default.
- W2790966707 cites W562098850 @default.
- W2790966707 doi "https://doi.org/10.1038/gim.2018.31" @default.
- W2790966707 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7609257" @default.
- W2790966707 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30728527" @default.
- W2790966707 hasPublicationYear "2019" @default.
- W2790966707 type Work @default.
- W2790966707 sameAs 2790966707 @default.
- W2790966707 citedByCount "54" @default.
- W2790966707 countsByYear W27909667072018 @default.
- W2790966707 countsByYear W27909667072019 @default.
- W2790966707 countsByYear W27909667072020 @default.
- W2790966707 countsByYear W27909667072021 @default.
- W2790966707 countsByYear W27909667072022 @default.
- W2790966707 countsByYear W27909667072023 @default.
- W2790966707 crossrefType "journal-article" @default.
- W2790966707 hasAuthorship W2790966707A5002329869 @default.
- W2790966707 hasAuthorship W2790966707A5002703388 @default.
- W2790966707 hasAuthorship W2790966707A5003696213 @default.
- W2790966707 hasAuthorship W2790966707A5003982307 @default.
- W2790966707 hasAuthorship W2790966707A5004853249 @default.
- W2790966707 hasAuthorship W2790966707A5008408499 @default.
- W2790966707 hasAuthorship W2790966707A5010287069 @default.
- W2790966707 hasAuthorship W2790966707A5010722476 @default.
- W2790966707 hasAuthorship W2790966707A5020425702 @default.
- W2790966707 hasAuthorship W2790966707A5021595831 @default.